NTX-1472

NTX-1472, also known as RO-6953958, is a vasopressin V 1A receptor antagonist which is under development for the treatment of social phobia (social anxiety disorder).

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

NTX-1472, also known as RO-6953958, is a vasopressin V 1A receptor antagonist which is under development for the treatment of social phobia (social anxiety disorder). It is taken orally. The drug is a potent and highly selective antagonist of the vasopressin V 1A receptor, with an affinity (K i ) of 0.5 nM and an inhibitory potency (K b ) of 0.22 nM.

Vasopressin V 1A receptor antagonists have been found to reduce amygdala activation in response to threatening social cues and to reduce anxiety-potentiated startle in humans, which are thought to be possible biomarkers of treatment response for social phobia. NTX-1472 was originated by Roche and is under development by Newleos Therapeutics.

As of January 2026, it is in phase 2 clinical trials for social phobia. The chemical structure of NTX-1472 does not yet appear to have been disclosed.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1358131434 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

5 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.